Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BI 653048 in Healthy Volunteers
NCT02217631Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2009
- Primary completion
- Mar 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BI 653048 in rheumatoid arthritis (RA) and Inflammatory Disorders (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with adverse events, Number of patients with clinically significant findings in vital signs and 3 more. Started Oct 2009; status: completed.
02
Drugs
BI 653048
03
Conditions
rheumatoid arthritis (RA)Inflammatory Disorders
Beyond the preview
Go deeper on NCT02217631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217631.